BioSpace News Archive

Life Without Ed® and Goodbye Ed, Hello Me® jewelry provides daily armor against eating disorders (a.k.a. Ed), and benefits the National Eating Disorders Association (NEDA).

CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens.

IQVIA uses advanced analytics and innovative technology, to find medium-to-high rates of flu in multiple U.S. markets; highest levels in parts of Montana, Nebraska and Texas

NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune.

Sanifit, a clinical-stage biopharmaceutical company focused on the treatment of conditions related to progressive vascular calcification, today announces the publication in the British Journal of Clinical Pharmacology of further data assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of its lead drug candidate SNF472 in haemodialysis (HD) patients.

MGI’s “Broadband” Sequencing Delivers Bandwidth to Achieve Genome for All Vision

Odonate Therapeutics, Inc. announced that it has initiated CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational, orally administered taxane, in patients with locally advanced or metastatic breast cancer who have not previously received a taxane.

It may seem counterintuitive, but having some extra body fat may be linked to an increased chance of surviving a stroke, according to a preliminary study released that will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, May 4 to 10, 2019.

Problem Gambling Awareness Month underway across MGM Resorts, highlighting March Madness

TGF-beta 1 & 3 are the principal drivers of fibrosis in systemic sclerosis and other indications, supporting broad utility of AVID200